Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
CASC2c
Specific or universal ncRNAs
Specific ncRNAs
Class
Long noncoding RNA
Biomarker
Yes
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
ERK1/ERK2/Ī²-catenin
Cancer name
Non-Small Cell Lung Cancer
Cancer site
Lung
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Down
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
86
Male patients
54
Female patients
32
Age range and number
50(<=55)+36(>55)
PMID
Description
It inhibited the proliferation and migration of NSCLC cells by inhibiting the expression of p-ERK1/2 and Ī²-catenin and reversed NSCLC cells' resistance to the chemotherapy drug cisplatin.
Tissue resource
matched cancer tissues and corresponding non-cancer tissues in NSCLS patients
non-small cell lung cancer cell lines H292
non-small cell lung cancer cell lines H226
non-small cell lung cancer cell lines H1975
non-small cell lung cancer cell lines H460
normal human lung bronchial epithelial cell lines BEAS-2B
Experiment
qRT-PCR,Western blot
Institute
American Type Culture Collection
Country
USA
Continent
Amercia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.